Dr G Thomas Budd talks to ecancer at the 2013 ASCO Annual Meeting in Chicago on a phase III randomised clinical trial that found low-dose weekly administration of paclitaxel and standard dose, every two weeks administration, resulted in equal progression-free survival for women with higher-risk early-stage breast cancer who have undergone surgery. However, researchers found that certain side effects were more common with the every two weeks regimen, suggesting the weekly schedule may be preferable.